Whether Vaxart will execute a reverse stock split depends on its future stock price performance and the necessity of maintaining compliance with Nasdaq Capital Market listing standards, which require a minimum bid price. While companies often consider reverse stock splits if their share prices drift below required thresholds for extended periods, such corporate actions require formal board approval and shareholder authorization. Unless necessitated by regulatory compliance rules to prevent potential delisting risks, management focuses primarily on advancing clinical trials and driving fundamental corporate value.